Suzhou Biosyntech Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 13921151340 +86 (512) 6300-1269 | |||
![]() |
sales2@biosyntech-suzhou.com sales@biosyntech-suzhou.com | |||
![]() |
QQ chat | |||
Chemical distributor since 2019 | ||||
chemBlink standard supplier since 2020 | ||||
Classification | Pharmaceutical intermediate >> Heterocyclic compound intermediate >> Pyrimidine compound >> Amine |
---|---|
Name | (R)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethan-1-amine |
Synonyms | (1R)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethanamine |
Molecular Structure | ![]() |
Molecular Formula | C10H11FN4 |
Molecular Weight | 206.22 |
CAS Registry Number | 2054317-97-2 |
SMILES | C[C@H](C1=CN=C(C=C1)N2C=C(C=N2)F)N |
Density | 1.3±0.1 g/cm3, Calc.* |
---|---|
Index of Refraction | 1.628, Calc.* |
Boiling Point | 347.4±37.0 ºC (760 mmHg), Calc.* |
Flash Point | 163.9±26.5 ºC, Calc.* |
* | Calculated using Advanced Chemistry Development (ACD/Labs) Software. |
Hazard Symbols |
|
---|---|
Hazard Statements | H302-H315-H319-H335 Details |
Precautionary Statements | P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P321-P330-P362-P403+P233-P405-P501 Details |
SDS | Available |
(R)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethan-1-amine is a small molecule belonging to the class of heteroaryl amines, structurally characterized by the presence of both a fluorinated pyrazole and a pyridine ring. These features often confer bioactivity relevant to drug discovery and development. Although the specific compound is not yet widely recognized under a common trade name or as part of a marketed pharmaceutical, its structural motifs are frequently encountered in the design of biologically active compounds, especially those targeting kinases, G protein-coupled receptors (GPCRs), or other enzymes involved in cellular signaling. The molecule includes several notable functional groups. The (R)-configuration at the ethan-1-amine chiral center may play a critical role in its biological interactions, as enantiomeric selectivity is often a key factor in pharmacodynamics and pharmacokinetics. The pyridine ring is commonly used in medicinal chemistry due to its ability to participate in hydrogen bonding and π–π interactions, which can enhance binding affinity to biological targets. The 4-fluoro-1H-pyrazol-1-yl substituent introduces a polar, electron-deficient heteroaromatic system that can improve metabolic stability and membrane permeability, while the fluorine atom often enhances receptor binding or modulates bioavailability. The inclusion of the fluoro-pyrazole moiety also suggests potential applications in kinase inhibition or anti-inflammatory research, as such heterocycles are frequently incorporated into scaffolds for targeting ATP-binding pockets in kinase enzymes. Moreover, fluorinated aromatic systems have been increasingly utilized in drug design for fine-tuning the physicochemical and pharmacokinetic properties of lead compounds. This compound may have originated in the context of high-throughput screening or structure-based drug design efforts, particularly within therapeutic areas like oncology, neurology, or inflammation. Synthetic approaches to such molecules typically involve cross-coupling reactions such as Suzuki or Buchwald-Hartwig amination to construct the aryl-heteroaryl bonds, followed by chiral amine introduction through asymmetric reduction or resolution strategies. In early discovery or preclinical research, molecules of this nature are often evaluated through in vitro biochemical assays, cell-based assays, and ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiling. If found to be active and selective, they may advance into in vivo efficacy studies or serve as templates for further optimization in drug development programs. While no specific therapeutic use for (R)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethan-1-amine is documented in the public domain, it exemplifies a design strategy that incorporates key medicinal chemistry principles such as heteroaromatic substitution, chirality, and strategic fluorination. These features collectively increase the likelihood of favorable pharmacological activity and the potential to serve as a lead compound in future drug discovery campaigns. |
Market Analysis Reports |
List of Reports Available for (R)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethan-1-amine |